Abstract
PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / chemical synthesis
-
Angiogenesis Inhibitors / pharmacology*
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Phthalazines / adverse effects
-
Phthalazines / chemical synthesis
-
Phthalazines / pharmacology*
-
Phthalazines / therapeutic use
-
Pyridines*
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
-
Structure-Activity Relationship
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Phthalazines
-
Pyridines
-
vatalanib
-
Receptors, Vascular Endothelial Growth Factor